Search results
20 gru 2019 · Objectives: Identify the mechanism of action of ciprofloxacin. Summarize the types of infections and bacterial coverage of ciprofloxacin and where it would be effective in a target population. Recognize the potential adverse events associated with ciprofloxacin therapy.
28 sie 2023 · Ciprofloxacin has FDA approval to treat urinary tract infections, sexually transmitted infections (gonorrhea and chancroid), skin, bone, joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, anthrax, plague, and salmonellosis.
Ciprofloxacin attains therapeutic concentrations in most tissues and body fluids. The results of clinical trials with ciprofloxacin have confirmed its clinical efficacy and low potential for adverse effects.
This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments.
Ciprofloxacin (international brand names: Cipro, Ciprobay, Ciproxin, Ciproxan, Bactiflox, etc.) is a broad-spectrum antibiotic of the semisynthetic fluoroquinolone class. It is one of the most widely used antibiotics in the world because of its efficacy, safety, and relatively low cost.
21 sie 2017 · Ciprofloxacin demonstrates a concentration-dependent permeability and it is widely distributed in body tissues and fluids including bile, prostatic tissues, gingival fluid, and lungs. Clearance of ciprofloxacin is by both renal and non-renal pathways (Micromedex, 2016).
27 lip 2021 · The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis.
